RESEARCH EXPERIENCE:
University of Minnesota Minneapolis, MN
-Effect of anti-angiogenic therapy on the growth and metastasis of breast cancer.
Roswell Park Cancer Institute Buffalo, NY
-Targeting CD20 and and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity against Non-Hodgkin's Lymphoma (NHL) Pre-Clinical Models.
-CMC-544 immuno-toxin is biologically active against Rituximab-sensitive and Rituximab-resistant cell lines and lymphoma xenografts.
MCP Hahnemann (Drexel) University Hospital Philadelphia, PA
-Pilot study of Annexin- V in patients with coronary artery disease for identification of ischemic myocardial regions.
-Comparison of two hour post dose Cyclosporine level (C2) and trough level (C0) in cardiac allograft recipients and their correlation with graft rejection and renal toxicity.
PUBLICAIONS:
-AAV-P 125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Therapy 16 September 2010; doi:10.1038/gt.2010.118.
-Targeting CD20 and CD22 with Rituximab in combination with CMC-544 results in improved anti-tumor activity against Non Hodgkin's Lymphoma pre clinical models. Blood (ASH Annual Meeting Abstracts) 2005 106: Abstract 1473.
-CMC544 immuno-toxin is biologically active against Rituximab-sensitive and Rituximab-resistant cell lines and lymphoma xenografts. Published in the NY ACP Abstract booklet in November 2004.
-Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity against Non-Hodgkin's Lymphoma (NHL) Pre-Clinical Models. Poster and Research presentation at the Austin Flint and John J O'Brien Research Symposium- State University of New York at Buffalo, NY- June 2006.